Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: Results of a prospective, randomized, double-blind, non-inferiority phase 3 trial - Raftopoulos, H; Cooper, W; O’Boyle, E (Support Care Cancer, 2015)
et al.